Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS4485054 A
Publication typeGrant
Application numberUS 06/432,686
Publication dateNov 27, 1984
Filing dateOct 4, 1982
Priority dateOct 4, 1982
Fee statusPaid
Also published asCA1205383A1, DE3335701A1
Publication number06432686, 432686, US 4485054 A, US 4485054A, US-A-4485054, US4485054 A, US4485054A
InventorsMichael Mezei, Fredric J. Nugent
Original AssigneeLipoderm Pharmaceuticals Limited
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US 4485054 A
Abstract
This invention provides an improved procedure for producing large multilamellar lipid vesicles (MLV), which may be used to encapsulate a biologically active material, particularly lipophilic substances. According to this invention, a lipid film is formed on inert, solid contact masses within a vessel, by evaporating an organic solvent therefrom. Subsequent agitation in the presence of an aqueous liquid, followed by a period in which the vessel remains undisturbed yields the multilamellar vesicles. The procedure permits the encapsulation of both hydrophilic and lipophilic materials.
Images(5)
Previous page
Next page
Claims(15)
We claim:
1. A process for producing large multilamellar lipid vesicles comprising the steps of:
(a) providing a vessel partially filled with inert, solid contact masses;
(b) providing a lipid component dissolved in a suitable organic solvent within said vessel;
(c) removing the organic solvent by evaporation so as to form a thin lipid film on the inner wall of said vessel and on the surfaces of said contact masses;
(d) thereafter adding an aqueous liquid to said vessel and agitating same to form an aqueous dispersion of lipid; and
(e) allowing said dispersion to stand essentially undisturbed for a time sufficient for the multilamellar vesicles to form.
2. The process of claim 1 wherein the lipid component is a phospholipid.
3. The process of claim 2 wherein the phospholipid is selected from the group consisting of phosphatidylcholines, lysophosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, and phosphatidylinositol.
4. The process of claim 3 wherein the phospholipid is provided in admixture with cholesterol.
5. The process of claim 3 wherein the phospholipid is provided in admixture with stearylamine or phosphatidic acid.
6. The process of claim 1 wherein a lipophilic biologically active material is provided in admixture with the lipid component.
7. The process of claim 6 wherein the lipophilic biologically active material comprises steroid hormones.
8. The process of claim 7 wherein the steroid hormone is progesterone.
9. The process of claim 1 where in the organic solvent is selected from the group consisting of chloroform, methanol and mixtures thereof.
10. The process of claim 1 where in the aqueous liquid contains a hydrophilic biologically active material.
11. The process of claim 1 wherein the inert, solid contact masses are made from glass, metal or a synthetic plastic.
12. The process of claim 11 wherein the inert, solid contact masses are spherical.
13. The process of claim 12 wherein the spherical, inert, solid contact masses have a diameter between 1 mm and 100 mm.
14. The process of claim 1 wherein the aqueous dispersion of lipid is allowed to stand essentially undisturbed for about 1 to 2 hours.
15. In a process for producing large multilamellar lipid vesicles of the type wherein a thin lipid film is formed on the inner wall of a vessel, an aqueous liquid is added to the vessel, the vessel is agitated to form an aqueous dispersion of lipid and the dispersion is allowed to stand essentially undisturbed for a time sufficient for the multilamellar vesicles to form, the improvement comprising also forming said thin lipid film on the surface of inert solid contact masses which partially fill said vessel.
Description
TECHNICAL FIELD

The present invention relates to the art of liposomal encapsulation. More specifically, the present invention relates to an improved procedure for producing large multilamellar lipid vesicles (MLV), which may be used to encapsulate a biologically active material, particularly lipophilic substances.

BACKGROUND ART

Liposomes or lipid vesicles are onion-like structures comprising a series of bimolecular lipid layers spaced from one another by an aqueous solution, the outermost layer being lipid. Liposomes have been advantageously used to encapsulate biologically active materials for a variety of uses. The prior art describes a number of techniques for producing synthetic liposomes. Most of these techniques relate to the formation of unilamellar vesicles. For example, U.S. Pat. No. 4,078,052 - Papahadjopoulos describes a procedure for producing large unilamellar vesicles (LUV). This particular procedure, however, is restricted to the lipid phosphalidyserine which was found to uniquely form the intermediate cochleate structure, apparently essential to the formation of the large lipid vesicles, in the presence of calcium cations.

A variety of other techniques have also been disclosed for producing small unilamellar vesicles (SUV). In one approach, a mixture of the lipid and an aqueous solution of the material to be encapsulated is warmed and then subjected to vigorous agitation and ultrasonic vibration. In another approach, U.S. Pat. No. 4,089,801 - Schneider, a mixture of a lipid, an aqueous solution of the material to be encapsulated, and a liquid which is insoluble in water is subjected to ultrasonication, whereby aqueous globules encased in a monomolecular lipid layer are formed dispersed in the water-insoluble liquid. The lipid vesicles are then formed by combining the first dispersion with a second aqueous fluid and then subjecting the mixture to centrifugation, whereby the globules are forced through the monomolecular lipid layer dividing the two phases, thereby forming the bimolecular lipid layer characteristic of liposomes. In still another approach, (O. Zumbuehl and H. G. Weder, Biochim. Biophys. Acta., 640: 252-262, 1981), the lipids and additives are solubilized with detergents by agitation or sonication, yielding defined mixed micelles. The detergents are then removed by dialysis.

Two alternate methods for the preparation of small unilamellar vesicles (SUV) that avoid the need for sonication are the ethanol injection technique (S. Batzri and E. D. Korn, Biochim. Biophys. Acta 198: 1015-1019, 1973) and the ether-infusion technique (D. Deamer and A. D. Bangham, Biochim. Biophys. Acta 443: 629-634, 1976). In these processes, the organic solution of lipids is rapidly injected into a buffer solution where it spontaneously forms liposomes.

A more recent method for preparing large unilamellar lipid vesicles (LUV) is the reverse phase evaporation technique described in U.S. Pat. No. 4,235,871 - Papahadjopoulos. This technique consists of forming a water-in-oil emulsion of (a) the lipids in an organic solvent and (b) the substances to be encapsulated in an aqueous buffer solution. Removal of the organic solvent under reduced pressure produces a mixture having a gel-like character which can then be converted to the lipid vesicles by agitation or by dispersion in an aqueous media.

U.S. Pat. No. 4,016,100 - Suzuki et al describes still another method of entrapping certain biologically active materials in unilamellar lipid vesicles by freezing an aqueous phospholipid dispersion of the biologically active materials and lipids.

For a comprehensive review of methods for preparing liposomes refer to a recent publication by Szoka and Papahadjopoulos (Ann. Rev. Biophys. Bioeng. 9: 467-508, 1980).

Methods for producing multilamellar lipid vesicles (MLV), are described by Bangham et al (J. Mol. Biol. 13: 238-252, 1965) and by Mezei and Gulasekharam, (Life Sci., 26: 1473-1477, 1980). The lipids and lipophilic substances are first dissolved in an organic solvent. The solvent is then removed under reduced pressure by rotary evaporation. The lipid residue forms a thin film on the wall of the container. Upon the addition of an aqueous solution, generally containing electrolytes or hydrophilic biologically active materials, large multilamellar lipsomes are formed. Small unilamellar vesicles can be prepared by sonication of the large multilamellar vesicles.

Most of these processes suffer from either low encapsulation efficiency or limitations in the types of materials that can be encapsulated or both. For example, most of these processes are limited to the encapsulation of hydrophilic materials, and cannot efficiently accommodate the encapsulation of lipophilic substances. Moreover, all of the currently available procedures, except the ones described by Bangham et al and by Mezei and Gulasekharam, are only suitable for the encapsulation of biologically active materials in oligolamellar, or unilamellar liposomes.

It is an object of the present invention to provide a process for encapsulating biologically active materials in large multilamellar lipid vesicles.

It is another object of this invention to provide a method for encapsulating biologically active materials that results in a significant increase in the encapsulation efficiency thereof.

It is still another object of this invention to provide a method of encapsulating biologically active materials in large multilamellar lipid vesicles that is not limited with respect to the material to be encapsulated and can efficiently accommodate both lipophilic and hydrophilic substances.

It is a further object of this invention to provide a procedure for encapsulating biologically active materials in a multilamellar lipid vesicle that can be conducted on a larger scale relative to prior art procedures.

DISCLOSURE OF THE INVENTION

These and other objects are met by the present invention which comprises a process for producing large multilamellar lipid vesicles comprising the steps of:

(a) providing a vessel partially filled with inert, solid contact masses;

(b) providing a lipid component dissolved in a suitable organic solvent within the vessel;

(c) removing the organic solvent by evaporation so as to form a thin lipid film on the inner wall of the vessel and on the surfaces of the contact masses;

(d) thereafter adding an aqueous liquid to the vessel and agitating the vessel to form an aqueous dispersion of lipid; and

(e) allowing the dispersion to stand essentially undisturbed for a time sufficient for the multilamellar vesicles to form.

If desired, the aqueous dispersion of the large multilamellar lipid vesicles can be further treated; for example, ultrasonication or filtration can be used to reduce the size of the vesicles or to change their structure to oligolamellar or unilamellar structures.

According to a known procedure, the multilamellar vesicles can be filtered through a series of polycarbonate filters, having decreasing pore sizes, so as to form the unilamellar vesicles.

It is specifically contemplated that hydrophilic and/or lipophilic biologically active substances will be encapsulated within the vesicles. A particularly advantageous consequence of the large-sized vesicles produced by this invention is that the risk of percutaneous transfer of the formulation is substantially reduced or eliminated. Therefore, this invention is particularly useful for encapsulating lipid soluble medicaments intended to produce local (i.e., topical) rather than systemic action.

As used in the specification and claims, the terms "biologically active material" or "biologically active substance" means a compound or composition which, when present in an effective amount, produces an effect in living cells or organisms.

DETAILED DESCRIPTION

As disclosed, this process differs from the technique proposed by Bangham in that the lipid film forming step is conducted in a vessel partially filled with inert, solid contact masses. This modification has a significant and unexpected impact on the overall encapsulation procedure. In particular, we have observed a significant increase in encapsulation efficiency, especially in the encapsulation of lipophilic substances.

Significant variation is possible in the size, size distribution, shape and composition of the contact masses. The principal characteristics of the contact masses are: (1) that the contact masses be inert to the materials used in the formulation, in other words there should be no unwanted interaction between the contact masses and the lipid, lipophilic substances, organic solvent or aqueous liquid employed, and (2) that the contact masses be solid throughout the processing steps, in other words the contact masses should not dissolve or disintegrate and should provide an appropriate solid surface for supporting the thin lipid film. Prior experimental testing has used glass beads or balls as the inert, solid contact masses and these materials have proven to be particularly suitable. It is also expected that metal balls, e.g., stainless steel and synthetic substances, e.g., plastics, will also be suitable in appropriate circumstances. While spherical contact masses are preferred, since they provide the maximum surface area in a given volume and are easily fluidized during the agitation step, other regular and irregular shapes could also be used.

The size of the contact masses used in any application will depend upon the scale of operation, the intensity of agitation and other factors that will be apparent to one skilled in this art. As an example, it is normally appropriate to use contact masses having a size such that the ratio of the vessel volume to the volume of an individual contact mass is between 50 and 50,000. Generally, spherical contact masses will have a diameter between 1.0 mm and 100 mm. It is also contemplated that the contact masses could have a range or distribution of sizes. However, our test work has shown that equally sized contact masses adequately satisfy the requirements of the invention. The number of contact masses employed will depend upon their shape and size, the size of the vessel, the volume of organic solvent used and the quantity of lipid and lipophilic substances dissolved. An appropriate number is used for increasing the surface area during the evaporation step and increasing the total area of the thin lipid film formed, but reserving sufficient volume within the vessel for movement of the contact masses during the agitation step.

The lipid vesicles of the present invention can be produced from phospholipids, neutral lipids, surfactants or any other related chemical compounds having similar amphiphilic properties. As is well known, these materials can be classified according to the formula A-B where A is a hydrophilic, generally polar group, e.g., a carboxyl group, and B is a hydrophobic, i.e., lipophilic, non-polar group, e.g., a long chain aliphatic hydrocarbon group. Suitable lipids include phosphatidylcholines, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, lysophosphatidylcholine and phosphatidylglycerol. In addition, other lipophilic additives may be used for selectively modifying the characteristics of the lipid vesicle, e.g., the stability and permeability of the vesicle membrance. Such other substances include stearylamine, phosphatidic acid, dicetyl phosphate, tocopherol, cholesterol, and lanolin extracts. From the foregoing, it should be appreciated that the composition of the lipid component can be substantially varied without significantly reducing the improvement in encapsulation efficiency provided by the present invention, and other lipids, in addition to those listed above, can be used as desired.

According to the present invention, the lipid component, together with any other lipophilic substances including biologically active materials, is initially dissolved in a suitable, generally non-polar, organic solvent. The organic solvent must be capable of being substantially removed from the lipid by evaporation and must not otherwise affect any of the lipophilic substances included in the formulation. Representative solvents include: ethers, esters, alcohols, ketones and various aromatic and aliphatic hydrocarbons, including fluorocarbons. The solvents may be used alone or in combination; for example, a 2:1 mixture of chloroform and methanol has been found to be suitable. The organic solvent is removed by evaporation, which can conveniently be accomplished by use of a rotary evaporator at temperatures generally between 20° and 60° C. and under a less-than-atmospheric pressure. As is well known, the evaporative conditions will strongly depend upon the physical properties of the organic solvent and the lipophilic materials used in the formulation.

After the lipid film forming step, the lipids are hydrated with an aqueous liquid to form an aqueous dispersion of lipid. The required agitation can be accomplished by the rotation or translation, i.e., vibration, of the vessel. An important feature of the present invention is that the presence of the inert, solid contact masses within the vessel provides an increased and consistent level of mechanical agitation, which enhances the formation of uniformly sized lipid vesicles. As is well known, this hydration step is conducted above the transition temperature of the lipid components.

The aqueous liquid may be pure water; but will generally be an aqueous solution of an electrolyte or a biologically active material. For example, an aqueous solution of sodium chloride or calcium chloride may be imployed. Additionally, active substances including pharmaceuticals such as, vitamins, hormones, enzymes, antibiotics and bactericides, and cosmetics such as, dyestuffs, perfumes and humectants may be included.

While most of the prior art procedures are limited to encapsulating hydrophilic materials, the present invention can also accomodate the encapsulation of hydrophobic, i.e., lipophilic materials. Testing has shown that lypophilic medicaments, e.g. progesterone, can be encapsulated at high efficiencies.

In other words, the present invention can be advantageously employed to encapsulate either hydrophilic or lipophilic substances or both. In the case of lipophilic materials, the substances to be encapsulated are co-dissolved with the lipids in the organic solvent prior to the lipid film forming step; while as noted above hydrophilic substances are conveniently added to the aqueous liquid used to disperse the lipid film.

After agitating the lipid-aqueous liquid mixture, the resulting dispersion is then allowed to remain undisturbed for a time sufficient to allow the lipid vesicles to form and mature. Generally, it will be sufficient to allow the vessel to stand undisturbed at room temperature for approximately one to two hours. The aqueous dispersion of the multilamellar lipid vesicles can then be recovered from the vessel containing the inert, solid contact masses. If desired, any non-incorporated active substances can be removed from the dispersion using known techniques such as repeated centrifugations, dialysis or column chromatography. The lipid vesicles can then be resuspended in any suitable electrolytic buffer for subsequent use.

Since the procedure described by Bangham is the only prior art process of which we are aware for encapsulating lipophilic materials in large multilamellar lipid vesicles, we conducted a series of experiments directly comparing the process of the present invention with the Bangham procedure. In particular, we compared the two procedures so as to determine their relative effectiveness in encapsulating lipophilic substances. The following examples will vividly demonstrate the significant and unexpected improvement in the encapsulation efficiency of lipophilic materials made possible by the present invention.

EXAMPLE I

In this example, multilamellar lipid vesicles are prepared using the procedure of this invention (Method A) and the procedure disclosed by Bangham (Method B). The materials used in preparing the lipid vesicles and the amounts thereof are listed below in Table 1. A small amount of progesterone labelled with Carbon 14 was mixed with a quantity of non-radioactive progesterone to facilitate the determination of its encapsulation efficiency.

              TABLE 1______________________________________DL alpha dipalmitoyl     22.2   mgphosphatidyl choline (DPPC)Cholesterol              5.0    mgProgesterone             5.0    mg(containing 0.5 uCi; 14 C)Calcium chloride solution (8 mM)                    5.0    ml______________________________________

In accordance with the method of this invention, Method A, the DPPC, cholesterol and progesterone were co-dissolved in a chloroform-methanol solvent (2:1) in a 50 ml round bottom vessel. Glass beads, having a diameter of 5 mm, were added to the vessel and the solvent was evaporated under vacuum in a rotary evaporator, thereby leaving a thin lipid film on the glass beads and on the vessel wall. A warm calcium chloride solution at 65° C. was then added to the vessel, and the mixture was vigorously shaken for one minute. Afterwards, the vessel was further agitated by rotating it in the rotary evaporator, without applying a vacuum, at 65° C. for 30 minutes. The resultant dispersion was allowed to stand for one hour.

According to the Bangham procedure, Method B, the DPPC, cholesterol and progesterone were similarly dissolved in a chloroform-methanol solvent (2:1) within a 50 ml round bottom vessel. The vessel did not contain any contact masses. The organic solvent was evaporated under vacuum in a rotary evaporator until a smooth, dry lipid film was observed on the wall of the vessel. A calcium chloride solution, heated to a temperature of 65° C. was then added to the contents of the vessel and the mixture was vigorously shaken in a 65° C. water bath for 30 minutes. The resultant dispersion was then allowed to stand for one hour.

After allowing the newly formed liposomal preparations to stand at room temperature for one hour, small aliquots (approximately 10 μl) of each of the preparations were examined under a microscope with a magnification of 475X using polarized light to verify the formation of the large multilamellar vesicles. The remaining portions of the liposomal preparations were filtered through polycarbonate filters having an 8 μm pore size. The filtrates were then centrifuged at 22,000 Xg for 15 minutes at 20°C. The supernatant was decanted and the centrifugate was resuspended in 5 ml of 8 mM aqueous calcium chloride solution. This procedure was repeated twice. The centrifugate separated from the final step of centrifugation was resuspended in 5.0 ml of 8 mM aqueous calcium chloride solution, and 10 μl aliquots from each preparation were used to calculate the encapsulation efficiency. The results are presented in Example III.

EXAMPLE II

The procedure of Example I was repeated three additional times, but in each case the formulation was changed to that listed in Tables 2, 3 and 4, respectively. In formulating the liposomes from the substances listed in Table 4, a 1000 ml vessel was substituted for the 50 ml vessel.

              TABLE 2______________________________________Phosphatidylcholine (purified)                   22.2   mgCholesterol             5.0    mgProgesterone (0.5 uCi; 14 C)                   5.0    mgCalcium Chloride (8 mM) 5.0    ml______________________________________

              TABLE 3______________________________________Dipalmitoyl phosphatidylcholine                    22.2   mgCholesterol              5.0    mgStearylamine             2.0    mgProgesterone (0.5 uCi; 14 C)                    5.0    mgCalcium Chloride (8 mM)  5.0    ml______________________________________

              TABLE 4______________________________________Dipalmitoyl phosphatidylcholine                    888.0  mgCholesterol              200.0  mgProgesterone (1.0 uCi: 14 C)                    200.0  mgCalcium Chloride (8 mM)  200.0  ml______________________________________
EXAMPLE III

The progesterone encapsulation efficiencies, using the test procedures described in Examples I and II, are listed in Table 5. As shown by these results, the present invention (Method A) provides a substantial and unexpected increase in the encapsulation efficiency of lipophilic materials as compared with the prior art (Method B) available for accomplishing the same result.

              TABLE 5______________________________________TABLE           % of EncapsulationFORMULATION     Method A  Method B______________________________________1               77.0      7.82               83.0      6.13               87.0      10.04               85.0      4.5______________________________________

In addition to enchancing encapsulation efficiency, the present invention also makes it possible to produce liposomes on a larger scale. The Bangham method can only produce small batches of liposomes (e.g., 100-200 ml) otherwise the encapsulation efficiency substantially decreases. The batch size when using our invention, however, can be significantly increased simply by increasing the surface area of the vessel and the inert, solid contact masses. This result is evidenced by the encapsulation efficiency data in Table 5 for the formulation of Table 4, in which a 1000 ml vessel was substituted for the 50 ml vessel used in the prior tests. This vessel also contained a larger amount of solid inert contact masses, providing much greater surface area for the lipid film formation. Consequently, the present invention makes the large scale manufacturing of liposomes possible.

While preferred embodiments of this invention have been discussed herein, those skilled in the art will appreciate that changes and modifications may be made without departing from the spirit and scope of this invention, as defined in and limited only by the scope of the appended claims.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3804776 *Dec 14, 1971Apr 16, 1974Fuji Photo Film Co LtdMethod of producing oil and fat encapsulated amino acids
US4016100 *Jan 26, 1976Apr 5, 1977Tanabe Seiyaku Co., Ltd.Method of preparing a controlled release liquid pharmaceutical composition
US4053585 *Jun 25, 1975Oct 11, 1977National Research Development CorporationImmunological preparations
US4078052 *Jun 30, 1976Mar 7, 1978The United States Of America As Represented By The Secretary Of Health, Education And WelfareLarge unilamellar vesicles (LUV) and method of preparing same
US4089801 *Jan 12, 1976May 16, 1978Battelle Memorial InstituteProcess for the preparation of liposomes
US4217344 *Dec 29, 1977Aug 12, 1980L'orealCompositions containing aqueous dispersions of lipid spheres
US4224179 *Aug 4, 1978Sep 23, 1980Battelle Memorial InstituteProcess for the preparation of liposomes in aqueous solution
US4235871 *Feb 24, 1978Nov 25, 1980Papahadjopoulos Demetrios PMethod of encapsulating biologically active materials in lipid vesicles
US4342826 *Jan 12, 1981Aug 3, 1982Collaborative Research, Inc.Immunoassay products and methods
Non-Patent Citations
Reference
1Bangham, A. D., Standish M. M., and Watkins, J. C., "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids", J. Mol. Biol., 13: 238-252, 1965.
2 *Bangham, A. D., Standish M. M., and Watkins, J. C., Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids , J. Mol. Biol., 13: 238 252, 1965.
3Batzri, S. and Korn, E. D., "Single Bilayer Liposomes Prepared Without Sonication", Biochim. Biophys. Acta., 298: 1015-1019, 1973.
4 *Batzri, S. and Korn, E. D., Single Bilayer Liposomes Prepared Without Sonication , Biochim. Biophys. Acta., 298: 1015 1019, 1973.
5Mezei, M. and Gulasekharam, V., "Liposomes-A Selective Drug Delivery System for the Topical Roue of Administration", Life Sciences, vol. 26, pp. 1473-1477, 1980.
6 *Mezei, M. and Gulasekharam, V., Liposomes A Selective Drug Delivery System for the Topical Roue of Administration , Life Sciences, vol. 26, pp. 1473 1477, 1980.
7Szoka, F. and Papahadjopoulos, D., "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)", Ann. Rev. Biophys. Bioeng., 9: 467-508, 1980.
8 *Szoka, F. and Papahadjopoulos, D., Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes) , Ann. Rev. Biophys. Bioeng., 9: 467 508, 1980.
9Zumbuehl, O. and Weder, H. G., "Liposomes of Controllable Size in the Range of 40 to 180 nm by Defined Dialysis of Lipid/Detergent Mixed Micelles", Biochim. Biophys. Acta., 640: 252-262, 1981.
10 *Zumbuehl, O. and Weder, H. G., Liposomes of Controllable Size in the Range of 40 to 180 nm by Defined Dialysis of Lipid/Detergent Mixed Micelles , Biochim. Biophys. Acta., 640: 252 262, 1981.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4619795 *Dec 24, 1984Oct 28, 1986Technicon Instruments Corp.Method for preparing lipid vesicles
US4673567 *Aug 8, 1985Jun 16, 1987Shionogi & Co., Ltd.Process for preparing liposome composition
US4728575 *Apr 10, 1985Mar 1, 1988Vestar, Inc.Contrast agents for NMR imaging
US4753788 *Jan 31, 1985Jun 28, 1988Vestar Research Inc.Method for preparing small vesicles using microemulsification
US4761288 *Sep 10, 1985Aug 2, 1988Mezei Associates LimitedMultiphase liposomal drug delivery system
US4830858 *Feb 11, 1985May 16, 1989E. R. Squibb & Sons, Inc.Spray-drying method for preparing liposomes and products produced thereby
US4853228 *Jul 28, 1987Aug 1, 1989Micro-Pak, Inc.Method of manufacturing unilamellar lipid vesicles
US4855090 *Jul 28, 1987Aug 8, 1989Micro-Pak, Inc.Method of producing high aqueous volume multilamellar vesicles
US4873035 *Nov 25, 1987Oct 10, 1989Abbott LaboratoriesPreparation of sized populations of liposomes
US4880635 *Jul 26, 1985Nov 14, 1989The Liposome Company, Inc.Dehydrated liposomes
US4891324 *Jan 7, 1987Jan 2, 1990Syntex (U.S.A.) Inc.Particle with luminescer for assays
US4897269 *Jun 27, 1988Jan 30, 1990Mezei Associates LimitedAdministration of drugs with multiphase liposomal delivery system
US4902466 *Dec 11, 1986Feb 20, 1990Ciba Corning Diagnostics Corp.Process for making lipid films suitable for liposomes
US4911928 *Mar 3, 1988Mar 27, 1990Micro-Pak, Inc.Paucilamellar lipid vesicles
US4917892 *Jun 28, 1988Apr 17, 1990Temple UniversityEncapsulated topical delivery system
US4917951 *Nov 24, 1987Apr 17, 1990Micro-Pak, Inc.Lipid vesicles formed of surfactants and steroids
US4935171 *Jan 27, 1989Jun 19, 1990Vestar, Inc.Method for vesicle formation
US4937078 *Aug 26, 1988Jun 26, 1990Mezei Associates LimitedLiposomal local anesthetic and analgesic products
US4938965 *Jul 22, 1987Jul 3, 1990Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian GovernmentOcular delivery of prophylactic agents
US4942038 *Aug 19, 1988Jul 17, 1990Micro Vesicular Systems, Inc.Encapsulated humectant
US5000958 *Jul 26, 1984Mar 19, 1991The Liposome Company, Inc.Enhancement of pharmaceutical activity
US5000960 *Jan 19, 1989Mar 19, 1991Micro-Pak, Inc.Protein coupling to lipid vesicles
US5017501 *Jan 19, 1989May 21, 1991Abbott LaboratoriesPreparation of uniformly sized liposomes encapsulating an aqueous liquid
US5019174 *Sep 21, 1989May 28, 1991Micro Vesicular Systems, Inc.Removing oil from surfaces with liposomal cleaner
US5019369 *Dec 1, 1988May 28, 1991Vestar, Inc.Method of targeting tumors in humans
US5019392 *Dec 20, 1988May 28, 1991Micro-Pak, Inc.Encapsulation of parasiticides
US5023086 *Dec 20, 1988Jun 11, 1991Micro-Pak, Inc.Encapsulated ionophore growth factors
US5068198 *Jan 13, 1989Nov 26, 1991Syntex (U.S.A.) Inc.Liquid single reagent for assays involving confining gels
US5104736 *Jun 26, 1989Apr 14, 1992Micro-Pak, Inc.Reinforced paucilamellar lipid vesicles
US5128139 *Feb 15, 1991Jul 7, 1992Nu Skin International, Inc.Composition containing liposome-entrapped grapefruit seed extract and method for making
US5133965 *Jun 8, 1989Jul 28, 1992Fountain Pharmaceuticals, Inc.Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution
US5160669 *Oct 16, 1990Nov 3, 1992Micro Vesicular Systems, Inc.Method of making oil filled paucilamellar lipid vesicles
US5188837 *Oct 3, 1991Feb 23, 1993Nova Pharmaceutical CorporationLipsopheres for controlled delivery of substances
US5198225 *Oct 2, 1989Mar 30, 1993Lvmh RechercheHydrated lipidic lamellar phases or liposomes based on ecdysteroids
US5202130 *Aug 31, 1989Apr 13, 1993The Johns Hopkins UniversitySuppression of eczematous dermatitis by calcium transport inhibition
US5221535 *Jan 23, 1992Jun 22, 1993Nova Pharmaceutical CorporationSustained release formulations of insect repellent
US5227165 *Jan 22, 1992Jul 13, 1993Nova Pharmaceutical CorporationLiposphere delivery systems for local anesthetics
US5234767 *Sep 12, 1991Aug 10, 1993Micro-Pak, Inc.Hybrid paucilamellar lipid vesicles
US5269979 *May 14, 1992Dec 14, 1993Fountain Pharmaceuticals, Inc.Method for making solvent dilution microcarriers
US5278300 *Apr 11, 1991Jan 11, 1994Akira Hasegawa4,6-o-hydroxyphosphoryl-glucosamine derivatives
US5304380 *Jun 8, 1992Apr 19, 1994Japan Tobacco Inc.Glucosamine derivative and liposome containing the same as membrane constituent
US5330689 *Mar 29, 1993Jul 19, 1994The Liposome Company, Inc.Entrapment of water-insoluble compound in alpha tocopherol-based vesicles
US5340588 *Jan 23, 1992Aug 23, 1994Nova Pharmaceutical CorporationLiposphere carriers of vaccines
US5340716 *Jun 20, 1991Aug 23, 1994Snytex (U.S.A.) Inc.Assay method utilizing photoactivated chemiluminescent label
US5366737 *Feb 10, 1993Nov 22, 1994Syntex (U.S.A.) Inc.N-[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N,-tetrasubstituted ammonium lipids and uses therefor
US5401511 *Oct 9, 1992Mar 28, 1995Baxter International Inc.Binding of protein and non-protein recognizing substances to liposomes
US5451408 *Mar 23, 1994Sep 19, 1995Liposome Pain Management, Ltd.Pain management with liposome-encapsulated analgesic drugs
US5545412 *Apr 3, 1995Aug 13, 1996Syntex (U.S.A.) Inc.N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5550289 *Apr 3, 1995Aug 27, 1996Syntex (U.S.A.) Inc.N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
US5578320 *Feb 24, 1993Nov 26, 1996The Liposome Company, Inc.Method of dehydrating liposomes using protective sugars
US5603872 *Oct 3, 1994Feb 18, 1997Baxter International Inc.Method of binding recognizing substances to liposomes
US5618732 *May 4, 1995Apr 8, 1997Behringwerke AgMethod of calibration with photoactivatable chemiluminescent matrices
US5622712 *May 4, 1994Apr 22, 1997Syntex (U.S.A.) Inc.N-[ω, (ω-1)-dialkyloxy]- and N-[ω, (ω-1)-dialkenyloxy]-alk-1-yl-N, N, N-tetrasubstituted ammonium lipids and uses therefor
US5628936 *May 31, 1995May 13, 1997Micro-Pak, Inc.Hybrid paucilamellar lipid vesicles
US5683715 *Jun 7, 1995Nov 4, 1997The Liposome Company, Inc.Taxane-containing phosphatidylcholine liposomes
US5702722 *Sep 12, 1995Dec 30, 1997Bracco Research S.A.Liposomes with enhanced entrapment capacity, method and use
US5709994 *Jun 6, 1995Jan 20, 1998Syntex (U.S.A.) Inc.Photoactivatable chemiluminescent matrices
US5776487 *Apr 19, 1996Jul 7, 1998Pasteur Sanofi DiagnosticsLiposome reagents for immunoassays
US5780319 *Apr 19, 1996Jul 14, 1998Pasteur Sanofi DiagnosticsImmunoassays to detect antiphospholipid antibodies
US5837279 *May 25, 1995Nov 17, 1998The Lipsome Company, Inc.Encapsulation of ionizable agents in liposomes
US5846561 *Dec 10, 1996Dec 8, 1998Baxter International Inc.Method of binding collagen recognizing substances to liposomes
US5853755 *Jun 10, 1997Dec 29, 1998Pharmaderm Laboratories Ltd.Biphasic multilamellar lipid vesicles
US5874105 *Jan 31, 1996Feb 23, 1999Collaborative Laboratories, Inc.Lipid vesicles formed with alkylammonium fatty acid salts
US5888536 *Oct 20, 1995Mar 30, 1999Chinoin Ltd.Liposome composition containing selegilin
US5895661 *Aug 12, 1997Apr 20, 1999Bracco Research S.A.Liposome vesicle precursors
US5922350 *Jun 16, 1997Jul 13, 1999The Liposome Company, Inc.Methods of dehydrating, storing and rehydrating liposomes
US5935572 *Jan 10, 1997Aug 10, 1999Collaborative Laboratories, Inc.Composition containing protease separate from glycosidase for removing nits in treating lice infestation
US5980937 *Aug 12, 1997Nov 9, 1999Bracco Research S.A.Liposomes with enhanced entrapment capacity and their use in imaging
US5993851 *Mar 13, 1998Nov 30, 1999Pharmaderm Laboratories, Ltd.Method for preparing biphasic multilamellar lipid vesicles
US6048545 *Jul 22, 1996Apr 11, 2000Biozone Laboratories, Inc.Liposomal delivery by iontophoresis
US6071535 *Feb 22, 1999Jun 6, 2000Collaborative Laboratories, Inc.Lipid vesicles formed with alkylammonium fatty acid salts
US6080211 *Feb 19, 1999Jun 27, 2000Igen, Inc.Lipid vesicle-based fuel additives and liquid energy sources containing same
US6139871 *Oct 20, 1998Oct 31, 2000The University Of British ColumbiaLiposome compositions and methods for the treatment of atherosclerosis
US6183774Aug 17, 1999Feb 6, 2001Collaborative Laboratories, Inc.Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6251581May 22, 1991Jun 26, 2001Dade Behring Marburg GmbhAssay method utilizing induced luminescence
US6312719May 28, 1999Nov 6, 2001The University Of British ColumbiaLiposome compositions and methods for the treatment of atherosclerosis
US6367479Apr 15, 1998Apr 9, 2002Esperion Luv Development, Inc.Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis, and pharmaceutical compositions and kit related thereto
US6387395Dec 2, 1994May 14, 2002Deborah A. EppsteinN-[1, (1-1) -dialkyloxy] - and N- [1, (1-1) -dialkenyloxy]- alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6479504Jun 16, 2000Nov 12, 2002The University Of Iowa Research FoundationAntagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
US6534018Nov 12, 1999Mar 18, 2003Optime Therapeutics, Inc.Method and apparatus for liposome production
US6576264Oct 17, 1996Jun 10, 2003Skyepharma Canada Inc.Insoluble drug delivery
US6596266Feb 20, 2001Jul 22, 2003Natural Science, Inc.Compositions containing minoxidil and saw palmetto for treating baldness
US6634576Aug 29, 2001Oct 21, 2003Rtp Pharma Inc.Milled particles
US6682761Apr 20, 2001Jan 27, 2004Rtp Pharma, Inc.Water-insoluble drug particle process
US6773719Aug 7, 2001Aug 10, 2004Esperion Luv Development, Inc.Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US6855277Nov 15, 2002Feb 15, 2005Optime Therapeutics, Inc.Method and apparatus for liposome production
US6855296Nov 12, 1999Feb 15, 2005Optime Therapeutics, Inc.Method and apparatus for liposome production
US6974593Jun 9, 2003Dec 13, 2005Jagotec AgInsoluble drug delivery
US6979456Mar 30, 1999Dec 27, 2005Jagotec AgAnticancer compositions
US7041705Mar 26, 2001May 9, 2006Jagotec AgInjectable aqueous dispersions of propofol
US7094756Dec 19, 2003Aug 22, 2006Vlaams Interuniversitair Instituut Voor Biotechnologie VzwAbin-mediated hepatitis protection
US7097849Aug 18, 1999Aug 29, 2006Jagotec AgInjectable aqueous dispersions of propofol
US7101570Nov 5, 2001Sep 5, 2006The University Of British ColumbiaLiposome compositions and methods for the treatment of atherosclerosis
US7122656Jul 9, 2004Oct 17, 2006Vlaams Interuniversitair Instituut Voor Biotechnologie VzwSplice variant of MyD88 and uses thereof
US7179484Nov 6, 2003Feb 20, 2007Azaya Therapeutics, Inc.Protein-stabilized liposomal formulations of pharmaceutical agents
US7229842May 19, 2005Jun 12, 2007Dade Behring Marburg GmbhMetal chelate containing compositions for use in chemiluminescent assays
US7244450Dec 4, 2003Jul 17, 2007Inex Pharmaceuticals CorporationCompositions and methods for treating lymphoma
US7247316Feb 18, 2004Jul 24, 2007Board Of Regents, The University Of Texas SystemCompositions and methods for treating lymphoma
US7255877Mar 31, 1999Aug 14, 2007Jagotec AgFenofibrate microparticles
US7273620May 19, 2003Sep 25, 2007University Of British ColumbiaTriggered release of liposomal drugs following mixing of cationic and anionic liposomes
US7311924Apr 3, 2003Dec 25, 2007Hana Biosciences, Inc.Compositions and methods for treating cancer
US7358085Feb 28, 2006Apr 15, 2008Sangamo Biosciences, Inc.Anti-angiogenic methods and compositions
US7407776Sep 17, 2004Aug 5, 2008Sangamo Biosciences, Inc.Engineered zinc finger proteins for regulation of gene expression
US7414026Oct 8, 2003Aug 19, 2008Vlaams Interuniversitair Instituut Voor Biotechnologie VzwInhibitors of NF-kappaB activation
US7534775Apr 7, 2005May 19, 2009Sangamo Biosciences, Inc.Methods and compositions for modulating cardiac contractility
US7723304Nov 5, 2002May 25, 2010Universidade Federal De Minas Gerais—UfmgSystems for delivery and release of angiotensin-(1-7)
US7732196Dec 6, 2007Jun 8, 2010Sangamo Biosciences, Inc.Anti-angiogenic methods and compositions
US7795209Oct 31, 2007Sep 14, 2010Sangamo Biosciences, Inc.Anti-angiogenic methods and compositions
US7811602May 16, 2005Oct 12, 2010Tekmira Pharmaceuticals CorporationLiposomal formulations comprising dihydrosphingomyelin and methods of use thereof
US7884180Sep 18, 2007Feb 8, 2011Compugen LtdPeptides which bind to G protein-coupled receptors
US7887836Mar 7, 2008Feb 15, 2011Hana Biosciences, Inc.Compositions and methods for treating lymphoma
US7893022Oct 31, 2007Feb 22, 2011Sangamo Biosciences, Inc.Anti-angiogenic methods and compositions
US7914796Jul 2, 2008Mar 29, 2011Sangamo Biosciences, Inc.Engineered cleavage half-domains
US7939105Nov 19, 1999May 10, 2011Jagotec AgProcess for preparing a rapidly dispersing solid drug dosage form
US7939106May 23, 2003May 10, 2011Jagotec AgProcess for preparing a rapidly dispersing solid drug dosage form
US7943134Mar 27, 2008May 17, 2011Academia SinicaCompositions and methods for identifying response targets and treating flavivirus infection responses
US8012946Jan 9, 2008Sep 6, 2011Sangamo Biosciences, Inc.Anti-angiogenic methods and compositions
US8034598Jun 23, 2009Oct 11, 2011Sangamo Biosciences, Inc.Engineered cleavage half-domains
US8039462Sep 19, 2006Oct 18, 2011Neuronascent, Inc.Methods and compositons for stimulating neurogenesis and inhibiting neuronal degeneration
US8206746Sep 30, 2002Jun 26, 2012Jagotec AgMicroparticles of water-insoluble substances
US8313925Mar 9, 2009Nov 20, 2012Sangamo Biosciences, Inc.Zinc finger proteins and method for inactivating a dhfr gene in a chinese hamster ovary cell
US8343539Jul 13, 2007Jan 1, 2013Regents Of The University Of MinnesotaCompounds that bind α5β1 integrin and methods of use
US8349801Sep 18, 2007Jan 8, 2013Compugen Ltd.Peptide ligands for G-protein coupled receptors
US8415329May 28, 1999Apr 9, 2013Jagotec AgThermoprotected compositions and process for terminal steam sterilization of microparticle preparations
US8460669May 12, 2011Jun 11, 2013Academia SinicaCompositions and methods for identifying response targets and treating flavivirus infection responses
US8501912Dec 8, 2008Aug 6, 2013The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesFilipil compositions and methods for treating cancer
US8584670Jan 8, 2009Nov 19, 2013Invention Science Fund I, LlcMethod, composition, and system to control pH in pulmonary tissue of a subject
US8586094May 2, 2003Nov 19, 2013Jagotec AgCoated tablets
US8609840Jun 20, 2008Dec 17, 2013Neuronascent, Inc.Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
USRE37002 *Jun 7, 1999Dec 26, 2000Matsushita Electric Industrial Co., Ltd.Lipid-dispersed solution, production thereof and use in determining lipid levels
USRE38407Jun 14, 2001Jan 27, 2004Delex Therapeutics Inc.Pain management with liposome-encapsulated analgesic drugs
EP0256090A1 *Jan 22, 1987Feb 24, 1988Liposome Co IncSolubilization of hydrophobic materials using lysophospholipid.
EP0744621A2 *May 21, 1996Nov 27, 1996Matsushita Electric Industrial Co., Ltd.Lipid-dispersion and process for producing the same
EP1985285A2Mar 31, 2000Oct 29, 2008Hana Biosciences, Inc.Compositions and methods for treating lymphoma
EP2207032A1Feb 8, 2001Jul 14, 2010Sangamo BioSciences, Inc.Cells expressing zinc finger protein for drug discovery
EP2213731A1May 23, 2007Aug 4, 2010Sangamo BioSciences, Inc.Variant foki cleavage half-domains
EP2266396A2Sep 24, 2002Dec 29, 2010Sangamo BioSciences, Inc.Modulation of stem cells using zinc finger proteins
EP2266537A2Mar 31, 2000Dec 29, 2010Hana Biosciences, Inc.Compositions and methods for treating cancer
EP2292274A1Sep 8, 2005Mar 9, 2011Sangamo BioSciences, Inc.Compositions and methods for protein production
EP2314614A1Feb 28, 2006Apr 27, 2011Sangamo BioSciences, Inc.Anti-angiogenic methods and compositions
EP2322143A1Jan 29, 1998May 18, 2011Pacira Pharmaceuticals, Inc.Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
EP2345417A1Dec 22, 2006Jul 20, 2011Vib VzwMeans and methods for mediating protein interference
EP2356995A2Nov 5, 2002Aug 17, 2011Universidade Federal de Minas Gerais-UFMGProcess of preparation of formulations of the peptide Angiotensin-(1-7) and its analogues, agonists and antagonists using cyclodextrins, liposomes and biodegradable polymers and/or mixtures and products thereof
EP2433496A1May 8, 2008Mar 28, 2012Burnham Institute for Medical ResearchTissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
EP2478766A2May 5, 2008Jul 25, 2012Burnham Institute for Medical ResearchTargeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
EP2492278A1Sep 18, 2007Aug 29, 2012Compugen Ltd.Antibodies against an agonist of G-protein coupled receptors and its use indiagnosis and therapy
EP2527435A2Jul 10, 2008Nov 28, 2012Sangamo BioSciences, Inc.Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
EP2615106A1Feb 7, 2011Jul 17, 2013Sangamo BioSciences, Inc.Engineered cleavage half-domains
EP2660318A1Feb 9, 2011Nov 6, 2013Sangamo BioSciences, Inc.Targeted genomic modification with partially single-stranded donor molecules
WO1986001103A1 *Aug 7, 1985Feb 27, 1986Liposome Co IncDehydrated liposomes
WO1991017424A1 *Apr 29, 1991Nov 14, 1991Vical IncIntracellular delivery of biologically active substances by means of self-assembling lipid complexes
WO1998003156A2 *Jul 22, 1997Jan 29, 1998Anthony E BeezerTopically applied composition for hormone replacement therapy
WO2005044792A2Oct 19, 2004May 19, 2005Jennifer M BurnsCompositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2007062399A2Nov 22, 2006May 31, 2007Univ TexasOncogenic ras-specific cytotoxic compound and methods of use thereof
WO2009007848A2Jul 11, 2008Jan 15, 2009Compugen LtdBioactive peptides and method of using same
WO2009019531A2Sep 18, 2007Feb 12, 2009Compugen LtdBioactive peptides and method of using same
WO2011043980A1Sep 30, 2010Apr 14, 2011Sanford Burnham Medical Research InstituteMethods and compositions related to clot-binding lipid compounds
WO2011075725A1Dec 20, 2010Jun 23, 2011Sanford-Burnham Medical Research InstituteMethods and compositions related to clot-binding compounds
WO2011079304A1Dec 23, 2010Jun 30, 2011Sanford-Burnham Medical Research InstituteMethods and compositions related to annexin 1-binding compounds
WO2011127405A1Apr 8, 2011Oct 13, 2011Sanford-Burnham Medical Research InstituteMethods and compositions for enhanced delivery of compounds
WO2012109387A1Feb 8, 2012Aug 16, 2012Halozyme, Inc.Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012118778A1Feb 28, 2012Sep 7, 2012Sanford-Burnham Medical Research InstituteTruncated car peptides and methods and compositions using truncated car peptides
WO2013093891A1Dec 21, 2012Jun 27, 2013Nuvo Research GmbhLiposomal chlorite or chlorate compositions
WO2014011237A1Mar 15, 2013Jan 16, 2014Sangamo Biosciences, Inc.Methods and compositions for the treatment of lysosomal storage diseases
WO2014011901A2Jul 11, 2013Jan 16, 2014Sangamo Biosciences, Inc.Methods and compositions for delivery of biologics
Classifications
U.S. Classification264/4.6, 514/951, 424/1.21, 514/962, 514/171, 428/402.2, 436/829, 424/450
International ClassificationA61K9/127
Cooperative ClassificationY10S514/951, Y10S436/829, Y10S514/962, A61K9/1277
European ClassificationA61K9/127P
Legal Events
DateCodeEventDescription
May 23, 1996FPAYFee payment
Year of fee payment: 12
Apr 17, 1992FPAYFee payment
Year of fee payment: 8
May 3, 1988FPAYFee payment
Year of fee payment: 4
Dec 3, 1982ASAssignment
Owner name: LIPODERM PHARMACEUTICALS, LIMITED, NOVA SCOTIA, CA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:MEZEI, MICHAEL;NUGENT, FREDRIC J.;REEL/FRAME:004065/0781
Effective date: 19821109